Patrick Holt Net Worth

The estimated Net Worth of Patrick Holt is at least $186 Tisíc dollars as of 22 January 2024. Patrick Holt owns over 14,426 units of Amarin Corp stock worth over $185,511 and over the last few years Patrick sold AMRN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Patrick Holt AMRN stock SEC Form 4 insiders trading

Patrick has made over 2 trades of the Amarin Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently Patrick bought 14,426 units of AMRN stock worth $15,724 on 22 January 2024.

The largest trade Patrick's ever made was buying 300,000 units of Amarin Corp stock on 16 August 2023 worth over $312,000. On average, Patrick trades about 104,809 units every 53 days since 2023. As of 22 January 2024 Patrick still owns at least 314,426 units of Amarin Corp stock.

You can see the complete history of Patrick Holt stock trades at the bottom of the page.

What's Patrick Holt's mailing address?

Patrick's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.

Insiders trading at Amarin Corp

Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum a David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.

What does Amarin Corp do?

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.

Complete history of Patrick Holt stock trades at Amarin Corp

Amarin Corp executives and stock owners

Amarin Corp executives and other stock owners filed with the SEC include:

• John Thero,
  President, Chief Executive Officer, Director
• Stephen Ketchum,
  President - Research and Development, Senior Vice President, Chief Scientific Officer
• Joseph Kennedy,
  Executive Vice President, General Counsel, Secretary, Strategic Initiatives
• Aaron Berg,
  Senior Vice President, Chief Commercial Officer
• Michael Kalb,
  Chief Financial Officer, Senior Vice President, Assistant Secretary
• Joseph Zakrzewski,
  Non-Executive Independent Director
• Dr. Steven B. Ketchum Ph.D.,
  Pres of R&D, Exec. VP and Chief Scientific Officer
• Dr. Steven B. Ketchum,
  Pres of R&D, Sr. VP and Chief Scientific Officer
• Michael W. Kalb,
  CFO, Sr. VP & Assistant Sec.
• Aaron D. Berg,
  Exec. VP & Pres of U.S.
• Elisabeth Schwartz,
  IR Contact Officer
• Jan van Heek,
  Non-Executive Independent Director
• David Stack,
  Non-Executive Independent Director
• Kristine Peterson,
  Non-Executive Independent Director
• Patrick O'Sullivan,
  Non-Executive Independent Director
• Lars Ekman,
  Non-Executive Independent Chairman of the Board
• Alan J. Wills B.A., BA (Zoology), M.B.A., MBA,
  Exec. VP of Corp. Bus. Devel.
• Jason M. Marks J.D.,
  Chief Legal Officer & Corp. Sec.
• Karim Mikhail,
  Pres, CEO & Director
• Donna Pasek,
  Sr. VP of HR
• Rami Daoud,
  Sr. VP of Corp. Devel.
• Alina Kolomeyer,
  Director of Communications
• Daniel S. Dunham,
  Sr. VP & Chief Pharmaceutical Compliance Officer
• Healthcare Partners Ltd. Fo...,
  Director
• Louis Iii Sterling,
  
• Oliver O'connor,
  
• Paul Cohen,
  
• Kostas D Odysseas,
  
• Mark Di Paolo,
  
• Steven B Ketchum,
  Chief Scientific Officer
• Murray Stewart,
  
• Karim Mikhail,
  President and CEO
• Jason M. Marks,
  EVP,Chief Global Legal Officer
• Alfonso G Zulueta,
  
• Erin S. Enright,
  
• Thomas Charles Reilly,
  EVP and CFO
• Geraldine Murphy,
  
• Adam Mark Berger,
  
• Diane E. Sullivan,
  
• Olsen Per Wold,
  Director
• Keith Horn,
  
• Jonathan Provoost,
  EVP, Chief Legal Officer
• Patrice Eadon Bonfiglio,
  
• Patrick Holt,
  President and CEO